{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:31:09Z","timestamp":1784860269673,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Anesth Analg Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite the growing body of evidence supporting the use of angiotensin II (ATII) in distributive shock, its integration into existing treatment algorithms requires careful consideration of factors related to patient comorbidities, hemodynamic parameters, cost-effectiveness, and risk\u2013benefit balance. Moreover, several questions regarding its use in clinical practice warrant further investigations. To address these challenges, a group of Italian intensive care specialists (the panel) developed a consensus process using a modified Delphi technique.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The panel defined five clinical questions during an online scoping workshop and then provided a short list of statements related to each clinical question based on literature review and clinical experience. A total of 20 statements were collected. Two coordinators screened and selected the final list of statements to be included in the online survey, which consisted of 17 statements. The consensus was reached when\u2009\u2265\u200975% of respondents assigned a score within the 3-point range of 1\u20133 (disagreement) or 7\u20139 (agreement).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, a consensus on agreement was reached on 13 statements defining the existing gaps in scientific evidence, the possibility of evaluating the addition of drugs with different mechanisms of action for the treatment of refractory shock, the utility of ATII in reducing the catecholamine requirements in the treatment of vasopressor-resistant septic shock, and the effectiveness of ATII in treating patients in whom angiotensin-converting enzyme activity is reduced or pharmacologically blocked. It was widely shared that renin concentration can be used to identify patients who most likely benefit from ATII to restore vascular tone. Thus, the patients who might benefit most from using ATII were defined. Lastly, some potential barriers to the use of ATII were described.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ATII was recognized as a useful treatment to reduce catecholamine requirements in treating vasopressor-resistant septic shock. At the same time, the need for additional clinical trials to further elucidate the efficacy and safety of ATII, as well as investigations into potential mechanisms of action and optimization of treatment protocols in patients with refractory distributive shock, emerged.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s44158-024-00186-y","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T05:02:17Z","timestamp":1723784537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The use of angiotensin II for the management of distributive shock: expert consensus statements"],"prefix":"10.1186","volume":"4","author":[{"given":"Giovanni","family":"Landoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cortegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bignami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"De Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Donadello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abele","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Grasselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Guarracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaola","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Paternoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Tritapepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Girardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"186_CR1","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1001\/jama.2018.6229","volume":"319","author":"KE Rudd","year":"2018","unstructured":"Rudd KE, Seymour CW, Aluisio AR, Augustin ME, Bagenda DS, Beane A et al (2018) Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) score with excess hospital mortality in adults with suspected infection in low- and middle-income countries. JAMA 319:2202","journal-title":"JAMA"},{"key":"186_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47:1181\u20131247","journal-title":"Intensive Care Med"},{"key":"186_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The third international consensus definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801","journal-title":"JAMA"},{"key":"186_CR4","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMra1208943","volume":"369","author":"JL Vincent","year":"2013","unstructured":"Vincent JL, De Backer D (2013) Circulatory shock. N Engl J Med 369:1726\u20131734","journal-title":"N Engl J Med"},{"issue":"45","key":"186_CR5","first-page":"757","volume":"115","author":"T Standl","year":"2018","unstructured":"Standl T, Annecke T, Cascorbi I, Heller AR, Sabashnikov A, Teske W (2018) The nomenclature, definition and distinction of types of shock. Dtsch Arztebl Int 115(45):757\u201368","journal-title":"Dtsch Arztebl Int"},{"key":"186_CR6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00134-016-4249-z","volume":"42","author":"DT Andreis","year":"2016","unstructured":"Andreis DT, Singer M (2016) Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med 42:1387\u20131397","journal-title":"Intensive Care Med"},{"key":"186_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/SHK.0000000000001022","volume":"49","author":"A Dargent","year":"2018","unstructured":"Dargent A, Nguyen M, Fournel I, Bourredjem A, Charles PE, Quenot JP (2018) EPISS study group: vasopressor cumulative dose requirement and risk of early death during septic shock: an analysis from the EPISS cohort. Shock 49:625\u2013630","journal-title":"Shock"},{"key":"186_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13054-015-0802-3","volume":"19","author":"TD Corr\u00eaa","year":"2015","unstructured":"Corr\u00eaa TD, Takala J, Jakob SM (2015) Angiotensin II in septic shock. Crit Care 19:98\u201398","journal-title":"Crit Care"},{"key":"186_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00134-023-07290-7","volume":"50","author":"R Bellomo","year":"2024","unstructured":"Bellomo R, Zarbock A, Landoni G (2024) Angiotensin II. Intensive Care Med 50:279\u2013282","journal-title":"Intensive Care Med"},{"key":"186_CR10","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1016\/j.clinthera.2019.09.014","volume":"41","author":"JM Allen","year":"2019","unstructured":"Allen JM, Gilbert BW (2019) Angiotensin II: a new vasopressor for the treatment of distributive shock. Clin Ther 41:2594\u20132610","journal-title":"Clin Ther"},{"key":"186_CR11","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/SHK.0000000000000807","volume":"47","author":"E Antonucci","year":"2017","unstructured":"Antonucci E, Gleeson PJ, Annoni F, Agosta S, Orlando S, Taccone FS et al (2017) Angiotensin II in refractory septic shock. Shock 47:560\u2013566","journal-title":"Shock"},{"key":"186_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s13054-014-0534-9","volume":"18","author":"LS Chawla","year":"2014","unstructured":"Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z et al (2014) Intravenous Angiotensin II for the Treatment of High-Output Shock (ATHOS trial): a pilot study. Crit Care 18:534\u2013534","journal-title":"Crit Care"},{"key":"186_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJMoa1704154","volume":"377","author":"A Khanna","year":"2017","unstructured":"Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H et al (2017) Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 377:419\u2013430","journal-title":"N Engl J Med"},{"key":"186_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s13054-017-1896-6","volume":"21","author":"LW Busse","year":"2017","unstructured":"Busse LW, McCurdy MT, Ali O, Hall A, Chen H, Ostermann M (2017) The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature. Crit Care 21:324","journal-title":"Crit Care"},{"key":"186_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s44158-024-00150-w","volume":"4","author":"I Coloretti","year":"2024","unstructured":"Coloretti I, Genovese A, Teixeira JP, Cherian A, Ferrer R, Landoni G et al (2024) Angiotensin II therapy in refractory septic shock: which patient can benefit most? A narrative review. J Anesth Analg Crit Care 4:13. https:\/\/doi.org\/10.1186\/s44158-024-00150-w","journal-title":"J Anesth Analg Crit Care"},{"key":"186_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ccc.2018.11.004","volume":"35","author":"IF Ukor","year":"2019","unstructured":"Ukor IF, Walley KR (2019) Vasopressin in vasodilatory shock. Crit Care Clin 35:247\u2013261","journal-title":"Crit Care Clin"},{"key":"186_CR17","doi-asserted-by":"publisher","first-page":"e0623","DOI":"10.1097\/CCE.0000000000000623","volume":"4","author":"M Quan","year":"2022","unstructured":"Quan M, Cho N, Bushell T, Mak J, Nguyen N, Litwak J et al (2022) Effectiveness of angiotensin II for catecholamine refractory septic or distributive shock on mortality: a propensity score weighted analysis of real-world experience in the medical ICU. Crit Care Explor 4:e0623","journal-title":"Crit Care Explor"},{"key":"186_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/MCC.0000000000000517","volume":"24","author":"BJ Wakefield","year":"2018","unstructured":"Wakefield BJ, Sacha GL, Khanna AK (2018) Vasodilatory shock in the ICU and the role of angiotensin II. Curr Opin Crit Care 24:277\u2013285","journal-title":"Curr Opin Crit Care"},{"key":"186_CR19","first-page":"685","volume":"43","author":"N Farina","year":"2018","unstructured":"Farina N, Bixby A, Alaniz C (2018) Angiotensin II brings more questions than answers. P T 43:685\u2013687","journal-title":"P T"},{"key":"186_CR20","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al (2001) The RAND\/UCLA appropriateness method user\u2019s manual. Available from: http:\/\/www.rand.org\/pubs\/monograph_reports\/MR1269.html"},{"key":"186_CR21","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J, Gordon AC, H\u00e9bert PC, Cooper DJ et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877\u201387","journal-title":"N Engl J Med"},{"issue":"1","key":"186_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13054-024-04910-6","volume":"28","author":"DE Leisman","year":"2024","unstructured":"Leisman DE, Handisides DR, Busse LW, Chappell MC, Chawla LS, Filbin MR et al (2024) ATHOS-3 Investigators. ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock. Crit Care 28(1):130. https:\/\/doi.org\/10.1186\/s13054-024-04910-6","journal-title":"Crit Care"},{"key":"186_CR23","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","volume":"202","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW et al (2020) Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med 202:1253\u20131261","journal-title":"Am J Respir Crit Care Med"},{"key":"186_CR24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/CCM.0000000000003092","volume":"46","author":"JA Tumlin","year":"2018","unstructured":"Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR et al (2018) Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med 46:949\u2013957","journal-title":"Crit Care Med"}],"container-title":["Journal of Anesthesia, Analgesia and Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-024-00186-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44158-024-00186-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-024-00186-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T05:03:22Z","timestamp":1723784602000},"score":1,"resource":{"primary":{"URL":"https:\/\/janesthanalgcritcare.biomedcentral.com\/articles\/10.1186\/s44158-024-00186-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1186\/s44158-024-00186-y","relation":{},"ISSN":["2731-3786"],"issn-type":[{"value":"2731-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required as the study not involve patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Giovanni Landoni has received speaker fees from Medis, Paion, and Viatris and consultancy fees from Paion and Viatris.Andrea Cortegiani received fee for lectures or advisory board membership from Gilead, MSD, Mundipharma, Pfizer, Viatris.Massimo Girardis has received honoraria for speaking at conferences and advisory services from Viatris and AOP Health related to the topic of this study.Giacomo Grasselli has received speaker fees from Getinge, Draeger Medical, Pfizer, MSD, Fisher&Paykel, Cook, Mundipharma; consultancy fees from Viatris and GSK; unrestricted research grants from NSD, Pfizer and Fier&Paykel.Luigi Tritapepe has received honoraria for advisory services from Viatris and for speaking from AOP health.Fabio Guarracino has received honoraria for advisory services from Viatris and speaker fees from Abbott, AOP Orphan, Edwards, Masimo and Orion.Gianpaola Monti received consultancy fee from Viatris.Katia Donadello has received consultancy fees from Viatris and speaker fees from MSD, Biotest, BD and Viatris.Abele Donati has received consultancy fees from Bioviix, Edwards, Grifols, Aspen, Viatris.Gianluca Paternoster has received honoraria for advisory services from Viatris, and speaker fees from AOP Orphan and Chiesi.Gennaro De Pascale has received honoraria for advisory services from Viatris.Elena Giovanna Bignami declared no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}